



**Contact:**

Staph Bakali  
Genocea Biosciences  
617.876.8191  
[Staph.Bakali@genocea.com](mailto:Staph.Bakali@genocea.com)

## **GENOCEA BIOSCIENCES APPOINTS JOHN SORVILLO VICE PRESIDENT OF BUSINESS DEVELOPMENT**

Biotech business development executive brings solid corporate partnering experience to cutting edge vaccine company

Cambridge, MA – July 27, 2009 – Genocea Biosciences, a leading vaccine discovery and development company, today announced that John M. Sorvillo, Ph.D. has joined the company as Vice President of Business Development.

“It is a great pleasure to welcome John to our team”, said Staph Leavenworth Bakali, Genocea’s Chief Executive Officer. “John’s extensive experience in business development and track record of success will be of great value to Genocea’s partnering and business development activities.”

“Genocea has developed one of the most exciting approaches to vaccine discovery and is accelerating vaccine development in multiple multi-billion dollar market segments,” said Dr. Sorvillo. “I am delighted to have the opportunity to be part of building a unique biotechnology company focused on novel prophylactic and therapeutic vaccines.”

Dr. Sorvillo was most recently Vice President of Business Development at Altus Pharmaceuticals [ALTU]. Before joining Altus, Dr. Sorvillo served as Chief Executive Officer of Bionaut Pharmaceuticals. Dr. Sorvillo was formerly Vice President of Business Development at ArQule [ARQL], where he was responsible for establishing many corporate technology and product collaborations with pharmaceutical companies. Prior to ArQule, Dr. Sorvillo held a variety of positions at OSI Pharmaceuticals [OSIP] (formerly Oncogene Science) leading up to his last position as Vice President and General Manager, Research Products Division. Dr. Sorvillo was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and received his Ph.D. in Immunology from the New York University Medical Center, Sackler Institute of Biomedical Sciences. He holds a B.A. in Biology from the City University of New York, Hunter College.

### **About Genocea Biosciences:**

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The company’s proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing vaccines for *chlamydia trachomatis* (a sexually transmitted disease with an estimated 90 million cases worldwide), *streptococcus pneumoniae* (pneumonia is the leading killer of children under the age of five worldwide) and other undisclosed targets. In 2008, Genocea was selected as “Best Vaccine Startup” at the World Vaccine Congress and was selected one of the 15 most exciting biotech startup companies by FierceBiotech. Genocea is backed by leading investors including Lux Capital Management, Polaris Venture Partners, SR One, Auriga Partners, Cycad Group, Morningside Ventures, and Alexandria Real Estate Equities. Visit [www.genocea.com](http://www.genocea.com) for more information.

###